Biogen's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Biogen develops, manufactures and markets therapies for patients living with serious neurological, autoimmune and hemato... Read more

Followers on Owler

11,620

Followers on Owler

Based on data from Biogen's latest SEC filings

Annual Revenue

Based on data from Biogen's latest SEC filings

Employees

CEO

Michel Vounatsos

CEO Approval Rating

65/100

OVERVIEW

Founded:

1978

Headquarters:

Cambridge, Massachusetts

Status:

PublicNASDAQBIIB

Industry Sector:

Biotechnology

SIC Code:

2836NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Novartis a competitor of Biogen?

I don't know

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

Sanofi is perceived as one of Biogen's biggest rivals. Sanofi's headquarters is in Paris, Île-de-France, and was founded in 1994. Sanofi operates in the Marine industry. Sanofi generates 281% of Biogen's revenue.

Bayer has been one of Biogen's top competitors. Bayer is a Public company that was founded in 1863 in Leverkusen, North Rhine-Westphalia. Bayer is in the Medical Research & Laboratories field. Compared to Biogen, Bayer has 96,024 more employees.

TEVA Pharmaceuticals is Biogen's #3 rival. TEVA Pharmaceuticals was founded in Petach Tikva, Center District} in 1901. TEVA Pharmaceuticals operates in the Pharmaceuticals industry. Compared to Biogen, TEVA Pharmaceuticals generates $2.5B more revenue.

Michel Vounatsos

CEO

- -

7,800

$14.4B

Paul Hudson

CEO

81/100

106,859

- -

$40.5B

Werner Baumann

Chairman & CEO

71/100

103,824

- -

$87.2B

Kaare Schultz

President & CEO

76/100

42,535

$7.7B

$16.9B

Vasant Narasimhan

CEO

85/100

118,393

- -

$47.4B

Alexander Hardy

CEO

73/100

14,717

$100M

$18.3B

Rehan Verjee

President

77/100

2,038

- -

$1.5B

Severin Schwan

CEO

65/100

3,700

- -

$898.3M

Robert A. Bradway

Chairman & CEO

62/100

19,200

$19M

$23.4B

Albert Bourla

Chairman & CEO

71/100

92,400

- -

$51.8B

Emma Walmsley

CEO

66/100

99,827

- -

$44.3B

The top 10 competitors in Biogen's competitive set are Sanofi, Bayer, TEVA Pharmaceuticals, Novartis, Genentech, EMD Serono, Roche, Amgen, Pfizer and GSK. Together they have raised over 7.8B between their estimated 670.1K employees. Biogen has 7,800 employees and is ranked 9th among it's top 10 competitors. The top 10 competitors average 55,572.

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$14.4B

Biogen's revenue is the ranked 9th among it's top 10 competitors. The top 10 competitors average 31.5B. Over the last four quarters, Biogen's revenue has grown by 5.2%. Specifically, in Q4 2019's revenue was $3.7B; in Q3 2019, it was $3.6B; in Q2 2019, it was $3.6B; in Q1 2019, Biogen's revenue was $3.5B.

Acquisitions

COMPANY ACQUIRED

ACQUISITION DATE

AMOUNT

DESCRIPTION

Nightstar Therapeutics Plc

Mar 2019

Source »

$800M

Nightstar develops novel therapies for the treatment of rare inherited retinal diseases.

These are all the companies that Biogen has acquired. Biogen's latest acquisition was Nightstar Therapeutics Plc in Mar 2019. Nightstar develops novel therapies for the treatment of rare inherited retinal diseases.

Investments

Samsung Bioepis develops and produces biopharmaceutical and biosimilar products.

$673.4M

Jul 28, 2018

Equity

Ionis is a drug discovery company that develops and commercializes ribonucleic acid-targeted therapeutics for cardiovascular and neurological diseases

$10M

Jul 16, 2017

Equity

Solid Biosciences develops and commercializes gene therapies for the treatment of Duchenne muscular dystrophy disorder.

$50M

Mar 29, 2017

Series C

Jan 25, 2018

Yumanity Therapeutics develops and commercializes drug-based therapies for the treatment of neurodegenerative diseases.

$51M

Feb 07, 2016

Series A

Rodin is a biotechnology company that discovers, develops and commercializes therapeutics for the treatment of neurologic diseases.

$17.3M

Jan 05, 2016

Equity

Nov 01, 2019

These are all the companies that Biogen has invested in. Biogen's latest investment was Nightstar Therapeutics Plc in Mar 2019. Nightstar develops novel therapies for the treatment of rare inherited retinal diseases.

Biogen News

See all articles »

March 30, 2020DirectorsTalk Interviews

Biogen Inc. - Consenus Indicates Potential 10.0% Upside

Biogen Inc. with ticker code (BIIB) now have 28 analysts covering the stock. The analyst consensus po... See more »

March 27, 2020themarketsdaily

Entera Bio (NASDAQ:ENTX) vs. Biogen (NASDAQ:BIIB) Critical Comparison

Entera Bio (NASDAQ:ENTX) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better... See more »

March 25, 2020The Business Journals: San Francisco Business Times

S.F. biotech races potential COVID-19 drug toward clinical trial

Vir Biotechnology Inc. teamed with WuXi Biologics and Biogen Inc. to rush a potential treatment for C... See more »

March 19, 2020FierceBiotechIT

Biogen sues over 'brazenly' copied aducanumab drug

Biogen has sued Boston-based biotech Creative Biolabs for allegedly selling copycat versions of its u... See more »

March 19, 2020Yicai Global

Biogen Fires Chinese Worker Who Fled US With a Trail of Covid-19 Cases

(Yicai Global) March 20 -- US biotech giant Biogen has laid off one of its US statisticians after the... See more »

March 18, 2020Reuters

Coronavirus delays Biogen's Spinraza for some patients

U.S. drugmaker Biogen Inc said on Wednesday that some patients on its drug Spinraza - which treats a ... See more »

March 17, 2020Associated Press News

Biogen donates $10M to fight the coronavirus pandemic

BOSTON (AP) - Biogen Inc., the Massachusetts biotech company linked to a cluster of COVID-19 cases st... See more »

Biogen Press Releases

See all articles »

December 20, 2018GlobeNewswire

Biogen Applauds Quebec Decision to Cover SPINRAZA (nusinersen) for a broad population of SMA Patients

MISSISSAUGA, Ontario, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Biogen Canada applauds the Government of Queb... See more »

October 29, 2018Central Charts

Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at CTAD

Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Tri... See more »

May 2, 2018StreetInsider

Biogen to Receive the Lifetime Achievement Award at Boston CEO, Taking Place May 9-10, 2018

Boston Biotech Conferences is hosting Boston CEO, a peer-to-peer meeting taking place May 9-10, 2018 ... See more »

March 21, 2018Business Wire

Global Neurodegenerative Diseases Drugs Market 2018-2023 - MS Set to Dominate with Tecfidera and Ocrevus - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Neurodegenerative Diseases Drugs Market to 2023 - MS Set to Domi... See more »

March 14, 2018MarketersMedia

Wired News - Biogen Presented New Interim Phase-2 Results from NURTURE Evaluating Efficacy and Safety of SPINRAZA at MDA Clinical Conference

Stock Monitor: Concordia Intl. Post Earnings ReportingLONDON, UK / ACCESSWIRE / March 14, 2018 / Acti... See more »

March 12, 2018Business Wire

New Data Presented at MDA Clinical Conference Show Benefit in Motor Function for Infants, Teens and Young Adults Treated With SPINRAZA® (nusinersen)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--New Data Presented at MDA Clinical Conference Show Benefit in Moto... See more »

March 9, 2018PR Newswire

Skyland Analytics Appoints James C. Mullen, Former Biogen and Patheon CEO, to Advisory Board

BOULDER, Colo., March 9, 2018 /PRNewswire/ -- Skyland Analytics, a leading developer of pharmaceutica... See more »